How much funding has 4D Molecular Therapeutics raised?

4D Molecular Therapeutics has raised $165.0M in total funding, most recently a Series C round.

Who are 4D Molecular Therapeutics's investors?

4D Molecular Therapeutics's investors include Viking Global, Jerel Davis.

When was 4D Molecular Therapeutics founded?

4D Molecular Therapeutics was founded in 2013.

Where is 4D Molecular Therapeutics headquartered?

4D Molecular Therapeutics is headquartered in Emeryville, California, United States.

What industry is 4D Molecular Therapeutics in?

4D Molecular Therapeutics operates in Healthcare.

How many employees does 4D Molecular Therapeutics have?

4D Molecular Therapeutics has 51-200 employees.

4D Molecular Therapeutics

IPO

Powering The Future Of Genetic Medicines

Public · Emeryville, United States · Founded 2013 · $165.0M raised

Healthcare

Headquarters: Emeryville, California
Employees: 51–200
Founded: 2013
Business Model: B2B
Website: 4dmoleculartherapeutics.com

Total Funding: $165.0M
Last Round: $75.0M Series CJun 2020
Rounds: 3
Type: Public

About

4D Molecular Therapeutics (4DMT) is a clinical-stage biopharma company inventing genetic medicines using its Therapeutic Vector Evolution platform to create customized AAV vectors for targeted gene delivery. The company focuses on retina and pulmonology indications, including wet AMD, DME, and cystic fibrosis. Founded in 2013, 4DMT is headquartered in Emeryville, California.

Summary

4D Molecular Therapeutics is a Healthcare company based in Emeryville, United States, founded in 2013. It has raised $165.0M in total across 3 rounds, most recently a $75.0M Series C round in Jun 2020. Investors include Viking Global and Jerel Davis.

LinkedIn X (Twitter)